The primary objective is to define the prevalence of serum anti-JCV antibody in relapsing
multiple sclerosis (MS) participants receiving Tysabri® (natalizumab) or being considered for
such treatment. Secondary objectives are to analytically validate the anti-JCV antibody assay
in a plasma matrix and to determine changes in anti-JCV antibody status over time.
Details
Lead Sponsor:
Biogen
Collaborators:
Elan Pharmaceuticals United BioSource Corporation United BioSource, LLC